## Edo Kaluski

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3065864/publications.pdf

Version: 2024-02-01

126907 88630 5,308 150 33 70 citations h-index g-index papers 176 176 176 5564 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Two-dimensional strain–a novel software for real-time quantitative echocardiographic assessment of myocardial function. Journal of the American Society of Echocardiography, 2004, 17, 1021-1029.	2.8	1,038
2	Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet, The, 1998, 351, 389-393.	13.7	520
3	High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. Journal of the American College of Cardiology, 2000, 36, 832-837.	2.8	199
4	The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. European Journal of Heart Failure, 2003, 5, 443-451.	7.1	151
5	Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. American Heart Journal, 2004, 147, 293-300.	2.7	151
6	A prospective study of posttraumatic stress symptoms and nonadherence in survivors of a myocardial infarction (MI). General Hospital Psychiatry, 2001, 23, 215-222.	2.4	140
7	Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes. Annals of Internal Medicine, 2019, 171, 190.	3.9	139
8	LINCS: L-NAME (a NO synthase inhibitor) In the treatment of refractory Cardiogenic Shock A prospective randomized study. European Heart Journal, 2003, 24, 1287-1295.	2.2	136
9	L-NMMA (a Nitric Oxide Synthase Inhibitor) is Effective in the Treatment of Cardiogenic Shock. Circulation, 2000, 101, 1358-1361.	1.6	133
10	Acute heart failure: a novel approach to its pathogenesis and treatment. European Journal of Heart Failure, 2002, 4, 227-234.	7.1	132
11	Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. American Heart Journal, 2003, 145, 622-627.	2.7	132
12	ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) Trial. Journal of the American College of Cardiology, 2007, 50, 509-513.	2.8	125
13	RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edema. Journal of the American College of Cardiology, 2003, 41, 204-210.	2.8	115
14	Accurate, Noninvasive Continuous Monitoring of Cardiac Output by Whole-Body Electrical Bioimpedance. Chest, 2004, 125, 1431-1440.	0.8	113
15	A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea. European Heart Journal, 2018, 39, 2291-2297.	2.2	107
16	Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. American Journal of Cardiology, 2003, 92, 222-226.	1.6	90
17	Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension – A Multi-Center Randomized Study. Cardiology, 2008, 109, 273-280.	1.4	89
18	Recent developments in cardiac output determination by bioimpedance: comparison with invasive cardiac output and potential cardiovascular applications. Current Opinion in Cardiology, 2004, 19, 229-237.	1.8	88

#	Article	IF	CITATIONS
19	Osteopontin in Cardiovascular Disease. Cardiology in Review, 2010, 18, 125-131.	1.4	80
20	The STAT-MI (ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction) Trial Improves Outcomes. JACC: Cardiovascular Interventions, 2011, 4, 222-227.	2.9	76
21	The effects of sinus membrane pathology on bone augmentation and procedural outcome using minimal invasive antral membrane balloon elevation Journal of Oral Implantology, 0, , 120305092100001.	1.0	59
22	Early Worsening Heart Failure in Patients Admitted for Acute Heart Failure: Time Course, Hemodynamic Predictors, and Outcome. Journal of Cardiac Failure, 2009, 15, 639-644.	1.7	56
23	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. Cardiology, 2011, 119, 96-105.	1.4	56
24	The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor) Tj ETQq0	0 <u>0 1</u> gBT	/Overlock 10
25	Minimally Invasive Antral Membrane Balloon Elevation Followed by Maxillary Bone Augmentation and Implant Fixation. Journal of Oral Implantology, 2006, 32, 26-33.	1.0	53
26	Association of Lowering Lowâ€Density Lipoprotein Cholesterol With Contemporary Lipidâ€Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2019, 8, e011581.	3.7	46
27	A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. European Journal of Preventive Cardiology, 2018, 25, 844-853.	1.8	43
28	Acute heart failure associated with high admission blood pressure - A distinct vascular disorder?. European Journal of Heart Failure, 2007, 9, 178-183.	7.1	42
29	Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 533-543.	1.8	42
30	Minimal heparinization in coronary angioplasty—how much heparin is really warranted?. American Journal of Cardiology, 2000, 85, 953-956.	1.6	41
31	Acute eosinophilic myocarditis: Diagnosis and treatment. Acute Cardiac Care, 2010, 12, 31-36.	0.2	37
32	Pulmonary edema: new insight on pathogenesis and treatment. Current Opinion in Cardiology, 2001, 16, 159-163.	1.8	36
33	Minimally Invasive Antral Membrane Balloon Elevation: Report of 36 Procedures. Journal of Periodontology, 2007, 78, 2032-2035.	3.4	36
34	Efficacy and safety of mechanical versus manual compression in cardiac arrest – A Bayesian network meta-analysis. Resuscitation, 2018, 130, 182-188.	3.0	36
35	Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with longâ€ŧerm prognosis?. Fundamental and Clinical Pharmacology, 2009, 23, 633-639.	1.9	35
36	Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. American Heart Journal, 2005, 150, 986.e1-986.e7.	2.7	33

#	Article	IF	CITATIONS
37	Nitric oxide synthase inhibitors in post-myocardial infarction cardiogenic shock-an update. Clinical Cardiology, 2006, 29, 482-488.	1.8	33
38	The Clinical Benefits and Mortality Reduction Associated With CatheterÂAblation in Subjects With AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2018, 4, 626-635.	3.2	33
39	Trends in Premature Mortality From Acute Myocardial Infarction in the United States, 1999 to 2019. Journal of the American Heart Association, 2022, 11, e021682.	3.7	32
40	Minimally Invasive Antral Membrane Balloon Elevation – Results of a Multicenter Registry. Clinical Implant Dentistry and Related Research, 2009, 11, e83-91.	3.7	29
41	Comparison of efficacy and safety of intracoronary sodium nitroprusside and intravenous adenosine for assessing fractional flow reserve. Catheterization and Cardiovascular Interventions, 2013, 81, 540-544.	1.7	26
42	Transcatheter vs surgical aorticâ€valve replacement in low―to intermediateâ€surgical―isk candidates: A metaâ€analysis and systematic review. Clinical Cardiology, 2017, 40, 974-981.	1.8	26
43	The Daily Incidence of Acute Heart Failure Is Correlated With Low Minimal Night Temperature: Cold Immersion Pulmonary Edema Revisited?. Journal of Cardiac Failure, 2006, 12, 114-119.	1.7	24
44	Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. European Journal of Heart Failure, 2008, 10, 196-200.	7.1	23
45	Early Thrombolytic Therapy Does Not Enhance the Recovery of the Right Ventricle in Patients with Acute Inferior Myocardial Infarction and Predominant Right Ventricular Involvement. Cardiology, 1990, 77, 40-49.	1.4	21
46	Patterns of leukocyte counts on admissions for acute heart failure â€" presentation and outcome â€" results from a community based registry. International Journal of Cardiology, 2011, 148, 17-22.	1.7	20
47	Acute <scp>ST</scp> â€elevation myocardial infarction due to septic embolism: A case report and review of management options. Catheterization and Cardiovascular Interventions, 2015, 85, E166-71.	1.7	20
48	Influence of conduction disturbances on clinical outcome in patients with acute myocardial infarction receiving thrombolysis (results from the ARGAMI-2 study). American Journal of Cardiology, 2004, 93, 76-80.	1.6	19
49	Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. European Journal of Heart Failure, 2005, 7, 815-819.	7.1	19
50	Non-invasive measurement of cardiac output by whole-body bio-impedance during dobutamine stress echocardiography: Clinical implications in patients with left ventricular dysfunction and ischaemia. European Journal of Heart Failure, 2006, 8, 136-140.	7.1	19
51	Coronary stenting with MGuard: from conception to human trials. Cardiovascular Revascularization Medicine, 2008, 9, 88-94.	0.8	19
52	Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban,) Tj ETQq0 0 0 301-307.	) rgBT /Ov 1.6	erlock 10 Tf 5 19
53	Minimally Invasive Antral Membrane Balloon Elevation in the Presence of Antral Septa: A Report of 26 Procedures. Journal of Oral Implantology, 2009, 35, 257-267.	1.0	18
54	Coronary stenting with MGuard: first-in-man trial. Journal of Invasive Cardiology, 2008, 20, 511-5.	0.4	18

#	Article	IF	Citations
55	Cardiogenic shock in a young female with multiple sclerosis. Resuscitation, 2006, 70, 153-157.	3.0	17
56	Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. American Journal of Cardiology, 1998, 82, 1024-1029.	1.6	16
57	Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. European Journal of Heart Failure, 2001, 3, 457-461.	7.1	16
58	Acute myocardial infarction due to left anterior descending coronary artery dissection after blunt chest trauma. Emergency Radiology, 2010, 17, 149-151.	1.8	16
59	Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2019, 13, 538-549.	1.5	16
60	Meta-analysis of Temporal and Surgical Risk Dependent Associations With Outcomes After Transcatheter Versus Surgical Aortic Valve Implantation. American Journal of Cardiology, 2019, 124, 1608-1614.	1.6	16
61	Sinus Rhythm Restoration after Atrial Fibrillation: The Clinical Value of Nâ€Terminal Proâ€BNP Measurements. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 955-960.	1.2	14
62	Coronary stenting with MGuard: extended follow-up of first human trial. Cardiovascular Revascularization Medicine, 2011, 12, 138-146.	0.8	14
63	Implantable cardioverter defibrillator in nonischemic cardiomyopathy: A systematic review and metaâ€analysis. Journal of Arrhythmia, 2018, 34, 4-10.	1.2	14
64	De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 209-215.	3.0	13
65	Delayed thrombocytopenia following abciximab therapy. International Journal of Cardiovascular Interventions, 2001, 4, 151-155.	0.5	12
66	The Effects of Sinus Membrane Pathology on Bone Augmentation and Procedural Outcome Using Minimal Invasive Antral Membrane Balloon Elevation. Journal of Oral Implantology, 2014, 40, 285-293.	1.0	12
67	Use of carbon dioxide as an intravascular contrast agent: A review of current literature. World Journal of Cardiology, 2017, 9, 715-722.	1.5	12
68	SCAI publications committee manual of standard operating procedures. Catheterization and Cardiovascular Interventions, 2020, 96, 145-155.	1.7	12
69	Transulnar access for coronary angiography and percutaneous coronary intervention. Journal of Invasive Cardiology, 2014, 26, 404-8.	0.4	12
70	Hemodynamic monitoring in acute heart failure. Critical Care Medicine, 2008, 36, S40-S43.	0.9	11
71	Automated contrast injectors for angiography: Devices, methodology, and safety. Catheterization and Cardiovascular Interventions, 2009, 74, 459-464.	1.7	10
72	Minimally Invasive Subnasal Elevation and Antral Membrane Balloon Elevation Along With Bone Augmentation and Implants Placement. Journal of Oral Implantology, 2012, 38, 365-376.	1.0	10

#	Article	IF	CITATIONS
73	Meta-Analysis of Antithrombotic Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 121, 1200-1206.	1.6	10
74	A Bayesian network meta-analysis of preventive strategies for contrast-induced nephropathy after cardiac catheterization. Cardiovascular Revascularization Medicine, 2019, 20, 29-37.	0.8	10
75	Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 913-920.	2.1	10
76	Rapid Clinical Assessment of Patients with Acute Heart Failure: First Blood Pressure and Oxygen Saturation – Is That All We Need?. Cardiology, 2009, 114, 75-82.	1.4	8
77	Instantaneous Wave-Free Ratio and Fractional Flow Reserve: Close, But Not Close Enough!. Journal of the American College of Cardiology, 2012, 59, 1915-1916.	2.8	8
78	Trans-ulnar catheterization and coronary interventions: From technique to outcomes. Cardiovascular Revascularization Medicine, 2017, 18, 299-303.	0.8	8
79	Coronary artery perforation complicated by recurrent cardiac tamponade: a case illustration and review. Cardiovascular Revascularization Medicine, 2017, 18, S30-S34.	0.8	8
80	Arteriotomy site complication during transcatheter aortic valve replacement: Ipsilateral wire protection and bailout. Cardiovascular Revascularization Medicine, 2018, 19, 724-730.	0.8	7
81	â€~Death and Life Are in the Power of the Tongue'?. Cardiology, 2009, 114, 39-41.	1.4	6
82	Management of cardiac arrest in 2005: an update. Israel Medical Association Journal, 2005, 7, 589-94.	0.1	6
83	Coronary stenting with M-Guard: feasibility and safety porcine trial. Journal of Invasive Cardiology, 2007, 19, 326-30.	0.4	6
84	Atropine-facilitated electrical cardioversion of persistent atrial fibrillation. American Journal of Cardiology, 2003, 92, 1119-1122.	1.6	5
85	Length of Hospital Stay After Percutaneous Coronary Interventions. Journal of Cardiovascular Nursing, 2008, 23, 345-348.	1.1	5
86	PCI of the right coronary artery via or under struts of stents protruding into the aorta. Journal of Invasive Cardiology, 2007, 19, E207-9.	0.4	5
87	Improved regional left ventricular function after successful satellite cell grafting in rabbits with myocardial infarction. European Journal of Heart Failure, 2003, 5, 751-757.	7.1	4
88	Whole-body electrical bio-impendance is accurate in non invasive determination of cardiac output: a thermodilution controlled, prospective, double blind evaluation. Journal of Cardiac Failure, 2004, 10, \$38-\$39.	1.7	4
89	Massive coronary perforation and shock: From appropriate labeling to appropriate calls. Acute Cardiac Care, 2009, 11, 181-186.	0.2	4
90	Cocaine-induced coronary thrombosis: what is the optimal treatment strategy. Cardiovascular Revascularization Medicine, 2011, 12, 133.e1-133.e6.	0.8	4

#	Article	IF	Citations
91	Percutaneous Coronary Intervention Versus Surgery in Left Main Stenosis–A Meta-Analysis and Systematic Review of Randomised Controlled Trials. Heart Lung and Circulation, 2018, 27, 138-146.	0.4	4
92	Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. European Journal of Preventive Cardiology, 2019, 26, 215-218.	1.8	4
93	Meta-analysis of duration of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention. European Journal of Preventive Cardiology, 2019, 26, 429-432.	1.8	4
94	Meta-analysis of long-term outcomes of percutaneous coronary intervention versus medical therapy in stable coronary artery disease. European Journal of Preventive Cardiology, 2019, 26, 433-436.	1.8	4
95	Optimizing primary PCI beyond "door to intervention timeâ€â€"are we there yet?. Cardiovascular Revascularization Medicine, 2010, 11, 84-90.	0.8	3
96	Prophylactic Pre-Operative Coronary Revascularization. Journal of the American College of Cardiology, 2010, 55, 1396-1397.	2.8	3
97	Renal Artery Stenosis-An Update. Postgraduate Medicine, 2013, 125, 43-50.	2.0	3
98	Have We Given Up on Intraâ€aortic Balloon Counterpulsation in Post–Myocardial Infarction Cardiogenic Shock?. Clinical Cardiology, 2013, 36, 704-710.	1.8	3
99	Atypical stress-induced cardiomyopathy: a case series. Acta Cardiologica, 2013, 68, 222-225.	0.9	3
100	Safety and efficacy of anti-thrombotic regimens in patients with percutaneous coronary intervention requiring oral anticoagulation: A traditional and network meta-analysis. Cardiovascular Revascularization Medicine, 2017, 18, 535-543.	0.8	3
101	Revascularization strategies in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 2018, 19, 647-654.	0.8	3
102	Right Heart Catheterization: Indications, Technique, Safety, Measurements, and Alternatives. Cardiology, 2003, 3, 225-235.	0.3	2
103	Adjunctive pharmacotherapy for coronary interventionsâ€"time to read the writing on the wall. Acute Cardiac Care, 2006, 8, 186-195.	0.2	2
104	Anteriorly displaced right coronary artery in acute myocardial infarction: what should every cardiologist know. Cardiovascular Revascularization Medicine, 2011, 12, 59-64.	0.8	2
105	Use of Antiplatelet Agents in Patients With Atherosclerotic Disease. Postgraduate Medicine, 2013, 125, 19-30.	2.0	2
106	lliofemoral peripheral orbital atherectomy for optimizing TAVR access: An innovative strategy in the absence of alternative access options. Cardiovascular Revascularization Medicine, 2018, 19, 71-76.	0.8	2
107	Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation. Cardiovascular Revascularization Medicine, 2019, 20, 147-152.	0.8	2
108	Wrist Artery Preservation. Cardiovascular Revascularization Medicine, 2020, 21, 293-294.	0.8	2

#	Article	IF	CITATIONS
109	Impella CP Dislodgment, Swap, or Removal: Current Practices. Journal of Invasive Cardiology, 2019, 31, 36-40.	0.4	2
110	Ipsilateral Protection and Bailout for Large-Bore Access. Journal of Invasive Cardiology, 2021, 33, E658-E661.	0.4	2
111	Coronary stent implantation without balloon predilatation: a single-center experience. International Journal of Cardiovascular Interventions, 1999, 2, 231-235.	0.5	1
112	Nitric Oxide Synthase Inhibitors in Refractory Cardiogenic Shock due to Myocardial Infarction after Percutaneous Coronary Intervention. Cardiology, 2005, 5, 161-167.	0.3	1
113	Interventional cardiology in Israel at 2005â€"state of practice. Acute Cardiac Care, 2007, 9, 104-110.	0.2	1
114	Glycoprotein IIb/IIIa inhibitors: questioning indications and treatment algorithms. Cardiovascular Revascularization Medicine, 2007, 8, 281-288.	0.8	1
115	Nitric oxide synthase inhibitors in cardiogenic shock: present and future. Future Cardiology, 2008, 4, 183-189.	1.2	1
116	The Role of Glycoprotein Ilb/Illa Inhibitors- A Promise Not Kept?. Current Cardiology Reviews, 2008, 4, 84-91.	1.5	1
117	Hypertension in African Americans with Heart Failure: Progression from Hypertrophy to Dilatation; Perhaps Not. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 61-68.	2.2	1
118	Pre-Procedural Forearm DSA: â€~lf You Don't Know Where You Are Going, You Will Wind up Someplace Else' (Yogi Berra). Cardiovascular Revascularization Medicine, 2018, 19, 901-902.	0.8	1
119	Angioplasty Balloon Entrapped Fully Inflated and Detached Within the Left Main Coronary Artery. Cardiovascular Revascularization Medicine, 2020, 21, 21-24.	0.8	1
120	The year since the guidelines: a concise update on recent advances in pulmonary hypertension. Minerva Cardiology and Angiology, 2016, 65, 68-73.	0.7	1
121	Massive Hematuria Due to a Femoroureteric Fistula A Late Complication of Aortofemoral Bypass Grafting —A Case Report. Vascular Surgery, 1992, 26, 71-76.	0.3	0
122	Nitrates for myocardial infarction. Lancet, The, 1998, 351, 1732-1733.	13.7	0
123	Periprocedural routines of coronary angioplastyextreme diversity with unrevealed consequences. International Journal of Cardiovascular Interventions, 1998, 1, 87-92.	0.5	0
124	Low dose tezosentan, an intravenous dual endothelin receptor antagonist, decreases type B-natruretic peptide levels in patients with acute decompensated heart failure. Journal of Cardiac Failure, 2003, 9, S94.	1.7	0
125	Integrilin Dose Optimization Using Cone Plate Analyzer – What Have We Learned Thus Far. Cardiology, 2004, 4, 151-156.	0.3	0
126	Outcome Of Patients With Cardiogenic Shock Treated By NO Synthase Inhibitors Is Predicted Only By Hemodynamic Response To Treatment And Not Baseline Characteristics. Results From The LINCS study. Journal of Cardiac Failure, 2004, 10, S80.	1.7	0

#	Article	IF	CITATIONS
127	Hemodynamic variables (cardiac power) and their changes during 6 hours are the strongest predictors of short-term outcome in acute heart failure. Journal of Cardiac Failure, 2004, 10, S31.	1.7	0
128	The daily incidence of acute heart failure is strongly correlated with cold weather conditions and air pollution. cold immersion pulmonary oedema revisited?. Journal of Cardiac Failure, 2004, 10, S94.	1.7	0
129	Non-invasive measurement of cardiac output by whole-body bio-impedance during dobutamine stress echocardiography: clinical implications in patients with left ventricular dysfunction and ischemia. Journal of Cardiac Failure, 2004, 10, S116.	1.7	0
130	Echocardiographic ejection fraction in patients with acute heart failure: weak correlations with cardiac contractility and short-term outcome. Journal of Cardiac Failure, 2004, 10, S132.	1.7	0
131	Hyponatremia in Acute Heart Failure – A Marker of Hyperglycemia and Reduced Renal Perfusion?. Journal of Cardiac Failure, 2006, 12, S78.	1.7	0
132	Troponin Increase in Acute Heart Failure – A Marker of Ischemia, a Measure of Severity or Both?. Journal of Cardiac Failure, 2006, 12, S78.	1.7	0
133	Acute Heart Failure Associated with High Admission Blood Pressure – A Very Common, yet Distinct Vascular Disorder?. Journal of Cardiac Failure, 2006, 12, S78.	1.7	0
134	Funneling: enhancing results of small-vessel stenting. Cardiovascular Revascularization Medicine, 2009, 10, 255-258.	0.8	0
135	"Buddy in jail―or "buried wire―method: A critical review. Catheterization and Cardiovascular Interventions, 2010, 75, 814-814.	1.7	0
136	RIPPLE EFFECTS OF A NOVEL D2B PATHWAY. Journal of the American College of Cardiology, 2010, 55, A109.E1013.	2.8	0
137	New Oral Anticoagulants: Good but Not Good Enough!. Journal of the American College of Cardiology, 2012, 60, 1434.	2.8	0
138	Complementary non-culprit revascularization during ST-elevation myocardial infarction…get to know your patient first to the editor. Catheterization and Cardiovascular Interventions, 2012, 79, 681-682.	1.7	0
139	CRT-400.28 Correlation Between Left Ventricular Outflow Tract Area by CCTA and TTE. JACC: Cardiovascular Interventions, 2016, 9, S50.	2.9	0
140	TCT-815 Meta-Analysis of Safety and Efficacy of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, B325.	2.8	0
141	COMPARISON OF OUTCOMES WITH DRUG ELUTING VERSUS BARE METAL STENT IN VERY ELDERLY POPULATION. Journal of the American College of Cardiology, 2019, 73, 240.	2.8	0
142	TRENDS OF CORONARY ARTERY DISEASE IN KAWASAKI DISEASE IN PATIENTS YOUNGER THAN 18 YEARS OLD FROM THE NATIONWIDE INPATIENT SAMPLE: 2005-2014. Journal of the American College of Cardiology, 2019, 73, 1778.	2.8	0
143	META-ANALYSIS OF SAFETY AND EFFICACY OF LOW DOSE RIVAROXABAN IN CORONARY ARTERY DISEASE. Journal of the American College of Cardiology, 2019, 73, 193.	2.8	0
144	Ipsilateral Ulnar Artery Access After Failed Radial Access: No Worries?. Cardiovascular Revascularization Medicine, 2021, 22, 89-90.	0.8	0

## Edo Kaluski

#	Article	IF	CITATIONS
145	Hyperbaric Oxygen Therapy Post-Primary PCI: Where Is It Going?. Cardiovascular Revascularization Medicine, 2021, 27, 20-21.	0.8	o
146	Arterial Tracking for Wrist-Based Interventions. Cardiovascular Revascularization Medicine, 2021, 29, 43-44.	0.8	0
147	Encasement of the Left Internal Mammary Arterial Graft to the Left Coronary Artery by Adenosquamous Carcinoma, an Unusual Tumor. The Open Cardiovascular Imaging Journal, 2009, 1, 13-15.	0.3	O
148	Stress Induced Cardiomyopathy Triggered by Acute Myocardial Infarction: A Case Series Challenging the Mayo Clinic Definition. American Journal of Case Reports, 2017, 18, 931-936.	0.8	0
149	The benefits and safety of external counterpulsation in symptomatic heart failure. Israel Medical Association Journal, 2006, 8, 687-90.	0.1	O
150	Tips and tricks for successful trans-EVAR TAVR: Buddy up!. Cardiovascular Revascularization Medicine, 2022, , .	0.8	0